BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

I-Mab Doses First Patient in Phase 3 Study of Lemzoparlimab for MDS in China

The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...

April 25, 2023 | News

OBiO Technology Launches New Super Factory in Shanghai with 29 GMP-Grade Production Lines for Gene and Cell Therapy

At the opening ceremony, OBiO showed the holistic process development capability and large-scale GMP manufacturing capacity in variety gene and cell therap...

April 25, 2023 | News

Ascentage Pharma Achieves EU GMP Compliance with Zero Deficiencies

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-...

April 25, 2023 | News

Everest Medicines Launches First-in-Disease Therapy for IgA Nephropathy in China's Hainan Boao Pilot Zone.

The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...

April 24, 2023 | News

CARsgen's CT041 receives IND clearance from NMPA for pancreatic cancer therapy.

Dr Raffaele Baffa, Chief Medical Officer of CARsgen, commented that "We are glad to receive the IND clearance from NMPA for the adjuvant treatment of ...

April 20, 2023 | News

Crystal Formulation Services Receives China Drug Manufacturing License for Milestone Formulation Capability

Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was r...

April 20, 2023 | News

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

A few months earlier, the Company's first product (BRG01) targeting relapsed/metastatic nasopharyngeal cancer has been granted IND approval by both the US ...

April 19, 2023 | News

Everest Medicines partners with Shanghai Pharma subsidiary to commercialize XERAVA in China

According to the MoU, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline) in China. SPH Kyuan'...

April 19, 2023 | News

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | News

Shanghai Biopharma Presents Phase I Data for Novel CAR-T in Advanced Liver Cancer

Early results indicate that C-CAR031 is well tolerated with promising anti-tumor activity seen and objective responses in several patients to date, includi...

April 18, 2023 | News

Ascentage Pharma's Three Studies Highlight New Potential Indications

"The data we presented at this year's AACR Annual Meeting highlight the three drug candidates' potential for clinical development and promising syn...

April 18, 2023 | News

NovoSense NST1002 improves CGM accuracy with glucose monitoring black tech.

Principle and technical difficulties of CGM CGM allows real-time monitoring of glucose concentration in subcutaneous tissue fluid by implanting glucose se...

April 18, 2023 | News

Zenshine's ZX-7101A Meets Primary Endpoint in Phase 2 Study for Adult Flu Treatment

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 17, 2023 | News

AffaMed Therapeutics Approved for Phase 3 Trial of DEXTENZA® in China for Eye Surgery Inflammation and Pain

In addition, AffaMed is pleased to announce that DEXTENZA has recently been approved in Macau, China for the treatment of ocular itchin...

April 17, 2023 | News

Stay Connected